Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2006 2
2010 1
2012 2
2013 1
2014 1
2015 3
2016 2
2017 5
2018 3
2019 3
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Current pharmacotherapy for cholestatic liver disease.
Carey EJ, Lindor KD. Carey EJ, et al. Expert Opin Pharmacother. 2012 Dec;13(17):2473-84. doi: 10.1517/14656566.2012.736491. Epub 2012 Oct 24. Expert Opin Pharmacother. 2012. PMID: 23094715 Review.
AREAS COVERED: This review will cover the current pharmacologic management of the most common causes of cholestatic liver disease in adults, including primary biliary cirrhosis, primary biliary cirrhosis-autoimmune hepatitis overlap syndrome, primary scler
AREAS COVERED: This review will cover the current pharmacologic management of the most common causes of cholestatic liver disease in adults, …
Fibrates and cholestasis.
Ghonem NS, Assis DN, Boyer JL. Ghonem NS, et al. Hepatology. 2015 Aug;62(2):635-43. doi: 10.1002/hep.27744. Epub 2015 Mar 23. Hepatology. 2015. PMID: 25678132 Free PMC article. Review.
Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment or disruption of bile production and causes intracellular retention of toxic bile constituents, including bile salts. ...
Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an …
Cholestatic liver diseases: new targets, new therapies.
Santiago P, Scheinberg AR, Levy C. Santiago P, et al. Therap Adv Gastroenterol. 2018 Aug 24;11:1756284818787400. doi: 10.1177/1756284818787400. eCollection 2018. Therap Adv Gastroenterol. 2018. PMID: 30159035 Free PMC article. Review.
Cholestatic liver diseases result from gradual destruction of bile ducts, accumulation of bile acids and self-perpetuation of the inflammatory process leading to damage to cholangiocytes and hepatocytes. If left untreated, cholestasis will lead to fibrosis, biliary cirrhos …
Cholestatic liver diseases result from gradual destruction of bile ducts, accumulation of bile acids and self-perpetuation of the inf …
Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis.
Mizuno S, Hirano K, Isayama H, Watanabe T, Yamamoto N, Nakai Y, Sasahira N, Tada M, Omata M, Koike K. Mizuno S, et al. J Hepatobiliary Pancreat Sci. 2015 Oct;22(10):766-70. doi: 10.1002/jhbp.281. Epub 2015 Aug 21. J Hepatobiliary Pancreat Sci. 2015. PMID: 26173026 Clinical Trial.
BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease. ...Bezafibrate was prescribed at 200 mg b.i.d. The primary endpoint was defined as improvements in liver function test (LFT) data after bezafibrate treatme …
BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease. ...Bezafibrate was prescribed …
Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S, Pares A, Reig A, Ben Belkacem K, Kemgang Fankem AD, Gaouar F, Poupon R, Housset C, Corpechot C, Chazouillères O. Lemoinne S, et al. Clin Res Hepatol Gastroenterol. 2018 Dec;42(6):521-528. doi: 10.1016/j.clinre.2018.06.009. Epub 2018 Aug 9. Clin Res Hepatol Gastroenterol. 2018. PMID: 30100231 Free article.
BACKGROUND & AIMS: In patients with primary sclerosing cholangitis (PSC), ursodeoxycholic acid (UDCA) treatment improves serum liver tests and surrogate markers of prognosis but has no proven effect on survival. Additional therapies are obviously needed. …
BACKGROUND & AIMS: In patients with primary sclerosing cholangitis (PSC), ursodeoxycholic acid (UDCA) treatment imp …
Emerging pharmacologic therapies for primary sclerosing cholangitis.
Cheung AC, Lazaridis KN, LaRusso NF, Gores GJ. Cheung AC, et al. Curr Opin Gastroenterol. 2017 May;33(3):149-157. doi: 10.1097/MOG.0000000000000352. Curr Opin Gastroenterol. 2017. PMID: 28257308 Free PMC article. Review.
PURPOSE OF REVIEW: The only currently approved treatment for primary sclerosing cholangitis (PSC) is liver transplantation, with a median time to transplant of 12-18 years after diagnosis. ...
PURPOSE OF REVIEW: The only currently approved treatment for primary sclerosing cholangitis (PSC) is liver transplantat …
New Therapeutic Strategies for Primary Sclerosing Cholangitis.
Williamson KD, Chapman RW. Williamson KD, et al. Semin Liver Dis. 2016 Feb;36(1):5-14. doi: 10.1055/s-0035-1571274. Epub 2016 Feb 12. Semin Liver Dis. 2016. PMID: 26870928 Review.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, which in the majority of patients progresses to liver transplantation or death. ...Gut-homing T cells may be important in the pathogenesis of PSC, and several agents are in developme
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, which in the majority of patients progress
Bezafibrate for the treatment of primary sclerosing cholangitis.
Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, Kawakubo K, Ito Y, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Isayama H, Kawabe T, Omata M, Koike K. Mizuno S, et al. J Gastroenterol. 2010 Jul;45(7):758-62. doi: 10.1007/s00535-010-0204-x. Epub 2010 Feb 3. J Gastroenterol. 2010. PMID: 20127368
BACKGROUND: It is known that bezafibrate decreases serum alkaline phosphatase (ALP) in patients with hyperlipidemia, and the efficacy of this drug for the treatment of primary biliary cirrhosis has been confirmed. However, there has been little evidence of its effic …
BACKGROUND: It is known that bezafibrate decreases serum alkaline phosphatase (ALP) in patients with hyperlipidemia, and the efficacy …
Factors predictive of the efficacy of bezafibrate therapy in patients with primary sclerosing cholangitis.
Mizuno S, Isayama H, Hirano K, Watanabe T, Takahara N, Kogure H, Matsubara S, Nakai Y, Tada M, Koike K. Mizuno S, et al. Hepatol Res. 2017 Oct;47(11):1102-1107. doi: 10.1111/hepr.12846. Epub 2017 Jan 17. Hepatol Res. 2017. PMID: 27874998
AIM: Primary sclerosing cholangitis (PSC) is a rare cholestatic disease. ...In this study, we assessed factors predictive of bezafibrate efficacy. METHODS: Twenty-five patients with PSC, who underwent bezafibrate therapy (400 mg per day) from No …
AIM: Primary sclerosing cholangitis (PSC) is a rare cholestatic disease. ...In this study, we assessed factors predicti …
Use of Fenofibrate for patients with primary Sclerosing Cholangitis.
Abdalla SM, Dejman A, Clark V, Levy C. Abdalla SM, et al. Clin Res Hepatol Gastroenterol. 2019 Jun;43(3):e33-e36. doi: 10.1016/j.clinre.2018.11.017. Epub 2019 Mar 14. Clin Res Hepatol Gastroenterol. 2019. PMID: 30880099 No abstract available.
29 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback